Neoantigen Cancer Vaccine Therapy

Neoantigen Cancer Vaccine Therapy

Neoantigen Cancer Vaccine Therapy

• July 8, 2022
• Read time: 2 minutes

What is Neoantigen Cancer Vaccine Therapy?

Neoantigens are specific cancer antigens identified by analyzing mutated genes in cancer cells (genomic analysis). Synthesized peptides based on specific neoantigens serve as cancer vaccines, designed to activate each patient's cancer-specific immune cells.

Characteristics of Neoantigen Cancer Vaccine Therapy

Since the vaccine uses only antigens expressed in cancer cells, it creates very high immunogenicity in the body. Current cancer antigens used in neoantigen cancer vaccines are antigens commonly present in cancer cells but also expressed in small amounts in normal cells. In contrast, neoantigens are antigens expressed only in cancer cells, making neoantigen cancer vaccines highly immunogenic.

Neoantigen Cancer Vaccine Therapy Helps Induce Anti-Tumor Immunity

Neoantigens are identified through next-generation sequencing analysis of cancer cell genes, with individualized analysis for each patient. Therefore, neoantigen peptide vaccine therapy has the characteristic of helping induce anti-tumor immunity.

Few Serious Adverse Effects

Neoantigen cancer vaccine therapy activates patients' own immune systems, resulting in few serious adverse effects. However, since it is an injection-based treatment, the injection site may experience temporary redness, itching, and patients may experience low-grade fever and discomfort.

Collect tissue and samples from surgery or biopsy (provide 10 glass slides containing tumor tissue >30%, unstained thickness of 10μm)

Analyze and select neoantigens (approximately one month required)

Synthesize neoantigens (approximately several weeks required)

Mix with immune adjuvants

Administer via subcutaneous injection (once every 1-2 weeks for a total of 4-7 injections, total treatment duration approximately 1.5-3 months)

Coordinate with other therapies (recommended by physician)

Immune checkpoint inhibitor therapy

Platinum Cancer Support Clinic: Neoantigen Cancer Vaccine Therapy

Genetic sequencing testing on tumor tissue or blood identifies tumor antigens and synthesizes multiple neoantigens, creating a personalized vaccine tailored to each patient's tumor and administered to induce anti-tumor immune responses. This clinical approach has extensive research and trials at Kyushu University and the University of Tokyo Institute of Medical Science Hospital. (Hijikata Yasuki et al, Clinical Immunology. 2016; Hijikata Yasuki et al, PLoS One. 2018)

Platinum Cancer Support Clinic Second Opinion Service

Analysis and recommendations for cancer treatment plans provided by the University of Tokyo Institute of Medical Science Hospital, Department of Palliative Care and Oncology, led by Dr. Hijikata Yasuki. Note: Please arrange online consultation appointments three days in advance.

University of Tokyo Medical Science Institute Hospital Physician: Hijikata Yasuki

University of Tokyo Institute of Medical Science Hospital Department of Palliative Care and Oncology Physician

Japanese Society of Internal Medicine Board-Certified Internist

Japanese Society of Internal Medicine Training Physician Supervisor

Japanese Cancer Treatment Certified Physician

Regenerative Medicine Certified Physician

Japan Medical Association Industry Certified Physician

Specializing in frontline cancer treatment and participating in cutting-edge cancer treatment clinical research. From immune cell culture to administration, this oncologist participates in the entire process of clinical research and is rare in combining cultivation and clinical experience.

If you have questions about neoantigen cancer vaccine therapy, second opinion appointments, or wish to schedule a consultation, please contact us—our dedicated team is ready to assist you.

• Immunotherapy

  (Solid Tumors) Is Keytruda Effective? (Solid Tumors) Rakuten Pharma RM-1995 Photoimmunotherapy Phase 1 Trial Initiated (Lung Cancer) Is Keytruda Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6